MRI as a central component of clinical trials analysis in brainstem glioma

A report from the Pediatric Brain Tumor Consortium (PBTC)

Tina Young Poussaint, Mehmet Kocak, Sridhar Vajapeyam, Roger I. Packer, Richard L. Robertson, Russell Geyer, Daphne Haas-Kogan, Ian F. Pollack, Gilbert Vezina, Robert Zimmerman, Soonmee Cha, Zoltan Patay, James M. Boyett, Larry E. Kun

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We report MRI findings from 2 pediatric clinical trials of diffuse intrinsic brainstem glioma (BSG) incorporating concurrent radiation therapy (RT) with molecularly targeted agents (gefitinib and tipifarnib). We determined associations of MRI variables with progression-free survival and overall survival and investigated effects of treatment on these variables. MRI (including diffusion and perfusion) was done before treatment, every 8 weeks (first year), every 12 weeks (thereafter), and at the end of treatment or disease progression. Reduced tumor volume (P < .0001) and tumor diffusion values (P<.0001) were apparent on the first post-RT/drug studies. Decreases in tumor volume correlated with pre-RT volume (P < .0001) and pre-RT diffusion values (P < .0001); larger decreases were noted for tumors with higher volumes and diffusion values. Patients with larger pre-RT tumors had longer progression-free survival (P < .0001). Patients with ≥25% decrease in tumor volume and diffusion values after RT had longer progression-free survival (P - .028) and overall survival (P - .0009). Enhancement at baseline and over time was significantly associated with shorter survival. Tumor diffusion values with baseline enhancement were significantly lower than those without (P - .0002). RT of BSG is associated with decreased tumor volume and intralesional diffusion values; patients with ≥25% decrease in values post-RT had relatively longer survival intervals, apparently providing an early imaging-based surrogate for relative outcomes. Patients with larger tumors and greater decreases in tumor volume and diffusion values had longer survival intervals. Tumor enhancement was associated with shorter survival, lower tumor diffusion values (increased cellularity), and a smaller drop in diffusion values after RT (P - .006). These associations justify continued investigation in other large clinical trials of brainstem glioma patients.

Original languageEnglish (US)
Pages (from-to)417-427
Number of pages11
JournalNeuro-oncology
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2011

Fingerprint

Brain Neoplasms
Glioma
Brain Stem
Radiotherapy
Clinical Trials
Pediatrics
Tumor Burden
Survival
Neoplasms
Disease-Free Survival
tipifarnib
Diffusion Magnetic Resonance Imaging
Disease Progression
Therapeutics
Perfusion
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

MRI as a central component of clinical trials analysis in brainstem glioma : A report from the Pediatric Brain Tumor Consortium (PBTC). / Poussaint, Tina Young; Kocak, Mehmet; Vajapeyam, Sridhar; Packer, Roger I.; Robertson, Richard L.; Geyer, Russell; Haas-Kogan, Daphne; Pollack, Ian F.; Vezina, Gilbert; Zimmerman, Robert; Cha, Soonmee; Patay, Zoltan; Boyett, James M.; Kun, Larry E.

In: Neuro-oncology, Vol. 13, No. 4, 01.04.2011, p. 417-427.

Research output: Contribution to journalArticle

Poussaint, TY, Kocak, M, Vajapeyam, S, Packer, RI, Robertson, RL, Geyer, R, Haas-Kogan, D, Pollack, IF, Vezina, G, Zimmerman, R, Cha, S, Patay, Z, Boyett, JM & Kun, LE 2011, 'MRI as a central component of clinical trials analysis in brainstem glioma: A report from the Pediatric Brain Tumor Consortium (PBTC)', Neuro-oncology, vol. 13, no. 4, pp. 417-427. https://doi.org/10.1093/neuonc/noq200
Poussaint, Tina Young ; Kocak, Mehmet ; Vajapeyam, Sridhar ; Packer, Roger I. ; Robertson, Richard L. ; Geyer, Russell ; Haas-Kogan, Daphne ; Pollack, Ian F. ; Vezina, Gilbert ; Zimmerman, Robert ; Cha, Soonmee ; Patay, Zoltan ; Boyett, James M. ; Kun, Larry E. / MRI as a central component of clinical trials analysis in brainstem glioma : A report from the Pediatric Brain Tumor Consortium (PBTC). In: Neuro-oncology. 2011 ; Vol. 13, No. 4. pp. 417-427.
@article{226ee66ddd564086a6430c5235977b63,
title = "MRI as a central component of clinical trials analysis in brainstem glioma: A report from the Pediatric Brain Tumor Consortium (PBTC)",
abstract = "We report MRI findings from 2 pediatric clinical trials of diffuse intrinsic brainstem glioma (BSG) incorporating concurrent radiation therapy (RT) with molecularly targeted agents (gefitinib and tipifarnib). We determined associations of MRI variables with progression-free survival and overall survival and investigated effects of treatment on these variables. MRI (including diffusion and perfusion) was done before treatment, every 8 weeks (first year), every 12 weeks (thereafter), and at the end of treatment or disease progression. Reduced tumor volume (P < .0001) and tumor diffusion values (P<.0001) were apparent on the first post-RT/drug studies. Decreases in tumor volume correlated with pre-RT volume (P < .0001) and pre-RT diffusion values (P < .0001); larger decreases were noted for tumors with higher volumes and diffusion values. Patients with larger pre-RT tumors had longer progression-free survival (P < .0001). Patients with ≥25{\%} decrease in tumor volume and diffusion values after RT had longer progression-free survival (P - .028) and overall survival (P - .0009). Enhancement at baseline and over time was significantly associated with shorter survival. Tumor diffusion values with baseline enhancement were significantly lower than those without (P - .0002). RT of BSG is associated with decreased tumor volume and intralesional diffusion values; patients with ≥25{\%} decrease in values post-RT had relatively longer survival intervals, apparently providing an early imaging-based surrogate for relative outcomes. Patients with larger tumors and greater decreases in tumor volume and diffusion values had longer survival intervals. Tumor enhancement was associated with shorter survival, lower tumor diffusion values (increased cellularity), and a smaller drop in diffusion values after RT (P - .006). These associations justify continued investigation in other large clinical trials of brainstem glioma patients.",
author = "Poussaint, {Tina Young} and Mehmet Kocak and Sridhar Vajapeyam and Packer, {Roger I.} and Robertson, {Richard L.} and Russell Geyer and Daphne Haas-Kogan and Pollack, {Ian F.} and Gilbert Vezina and Robert Zimmerman and Soonmee Cha and Zoltan Patay and Boyett, {James M.} and Kun, {Larry E.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1093/neuonc/noq200",
language = "English (US)",
volume = "13",
pages = "417--427",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - MRI as a central component of clinical trials analysis in brainstem glioma

T2 - A report from the Pediatric Brain Tumor Consortium (PBTC)

AU - Poussaint, Tina Young

AU - Kocak, Mehmet

AU - Vajapeyam, Sridhar

AU - Packer, Roger I.

AU - Robertson, Richard L.

AU - Geyer, Russell

AU - Haas-Kogan, Daphne

AU - Pollack, Ian F.

AU - Vezina, Gilbert

AU - Zimmerman, Robert

AU - Cha, Soonmee

AU - Patay, Zoltan

AU - Boyett, James M.

AU - Kun, Larry E.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - We report MRI findings from 2 pediatric clinical trials of diffuse intrinsic brainstem glioma (BSG) incorporating concurrent radiation therapy (RT) with molecularly targeted agents (gefitinib and tipifarnib). We determined associations of MRI variables with progression-free survival and overall survival and investigated effects of treatment on these variables. MRI (including diffusion and perfusion) was done before treatment, every 8 weeks (first year), every 12 weeks (thereafter), and at the end of treatment or disease progression. Reduced tumor volume (P < .0001) and tumor diffusion values (P<.0001) were apparent on the first post-RT/drug studies. Decreases in tumor volume correlated with pre-RT volume (P < .0001) and pre-RT diffusion values (P < .0001); larger decreases were noted for tumors with higher volumes and diffusion values. Patients with larger pre-RT tumors had longer progression-free survival (P < .0001). Patients with ≥25% decrease in tumor volume and diffusion values after RT had longer progression-free survival (P - .028) and overall survival (P - .0009). Enhancement at baseline and over time was significantly associated with shorter survival. Tumor diffusion values with baseline enhancement were significantly lower than those without (P - .0002). RT of BSG is associated with decreased tumor volume and intralesional diffusion values; patients with ≥25% decrease in values post-RT had relatively longer survival intervals, apparently providing an early imaging-based surrogate for relative outcomes. Patients with larger tumors and greater decreases in tumor volume and diffusion values had longer survival intervals. Tumor enhancement was associated with shorter survival, lower tumor diffusion values (increased cellularity), and a smaller drop in diffusion values after RT (P - .006). These associations justify continued investigation in other large clinical trials of brainstem glioma patients.

AB - We report MRI findings from 2 pediatric clinical trials of diffuse intrinsic brainstem glioma (BSG) incorporating concurrent radiation therapy (RT) with molecularly targeted agents (gefitinib and tipifarnib). We determined associations of MRI variables with progression-free survival and overall survival and investigated effects of treatment on these variables. MRI (including diffusion and perfusion) was done before treatment, every 8 weeks (first year), every 12 weeks (thereafter), and at the end of treatment or disease progression. Reduced tumor volume (P < .0001) and tumor diffusion values (P<.0001) were apparent on the first post-RT/drug studies. Decreases in tumor volume correlated with pre-RT volume (P < .0001) and pre-RT diffusion values (P < .0001); larger decreases were noted for tumors with higher volumes and diffusion values. Patients with larger pre-RT tumors had longer progression-free survival (P < .0001). Patients with ≥25% decrease in tumor volume and diffusion values after RT had longer progression-free survival (P - .028) and overall survival (P - .0009). Enhancement at baseline and over time was significantly associated with shorter survival. Tumor diffusion values with baseline enhancement were significantly lower than those without (P - .0002). RT of BSG is associated with decreased tumor volume and intralesional diffusion values; patients with ≥25% decrease in values post-RT had relatively longer survival intervals, apparently providing an early imaging-based surrogate for relative outcomes. Patients with larger tumors and greater decreases in tumor volume and diffusion values had longer survival intervals. Tumor enhancement was associated with shorter survival, lower tumor diffusion values (increased cellularity), and a smaller drop in diffusion values after RT (P - .006). These associations justify continued investigation in other large clinical trials of brainstem glioma patients.

UR - http://www.scopus.com/inward/record.url?scp=79955776393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955776393&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq200

DO - 10.1093/neuonc/noq200

M3 - Article

VL - 13

SP - 417

EP - 427

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 4

ER -